Federal Reimbursement Expert Ruben J. King-Shaw, Jr. Joins Lucid’s Board of Directors - Citybizlist New York

a leader in FDA-approved noninvasive cellular imaging, today announced that Ruben J. King-Shaw, Jr. was appointed to the Company's Board of Directors on December 14, 2010. Mr. King-Shaw brings to Lucid a wealth of experience in medical reimbursement and healthcare services
He currently serves on Medicare's Program Advisory and Oversight Commission, which advises the Obama administration on effective value-based procurement strategies for healthcare reform. He also is Chief Executive Officer of Mansa Equity Partners, Inc., a private equity and investment advisory firm specializing in supporting the growth of healthcare companies.
"My background allows me to identify companies with innovative technologies that can redefine the standard of care and ensure savings to the U.S. healthcare system. Lucid's VivaScope and VivaNet products have the potential to do both," said Mr. King-Shaw. "Lucid's VivaScopes provide a noninvasive, painless and accurate way to reduce the cost of early skin cancer detection by allowing clinicians to distinguish benign from malignant lesions at the point and time of care. In the United States alone, about $2.2 billion is spent each year biopsying and diagnosing suspicious skin lesions that are determined to be benign."
Mr. King-Shaw has extensive experience in healthcare policy, economics and finance. He served as Chief Operating Officer and Deputy Administrator of the Centers for Medicare and Medicaid Services from 2001 through 2003, and prior to that was Secretary of the Florida Agency for Health Care Administration. In 2002 President Bush named King-Shaw to the President's New Freedom Commission on Mental Health, and in 2005 New York Governor George Pataki appointed King-Shaw to the Commission on Health Care Facilities in the 21st Century.
"Ruben brings with him extensive experience in Federal reimbursement policies and procedures that is directly relevant to Lucid," said William Shea, Chairman of the Board of Directors at Lucid. "Specifically, since reimbursement is a key factor in driving adoption of a new medical technology, Ruben's experience and Washington, DC relationships will be important assets to Lucid as the Company moves forward in rolling out its VivaScopes and the VivaNet System."
"Ruben is a results-oriented executive who knows what drives adoption of new medical technology by participants in the U.S. healthcare system," said Jay Eastman, Chief Executive Officer of Lucid. "Lucid, which is established as a leader in accurate, noninvasive assessment and diagnosis of skin cancer, will benefit from Ruben's knowledge as our team moves rapidly to drive adoption of our VivaNet platform. We are delighted that he has recognized Lucid's commercial potential and agreed to join our Board of Directors."